Lokavant, Inc.

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025. In this discussion, Konstantina Katcheves , senior VP of innovative global business development at Teva Pharmaceuticals discusses her takeaways from her time at the World Economic Forum (WEF). She stresses the importance of data-driven healthcare and AI innovation in the pharmaceutical value chain, and the critical need to address global health equity, particularly women’s health. Within the conversation, Katcheves also addresses the industry’s challenge in regaining patient trust, suggesting that empowering patients to use their data for health decisions could improve trust. Key Takeaways There is a gap in global health equity, particularly in women’s health, and the critical role of women in healthcare decisions was emphasized. The life sciences industry in the US is expected to continue leading initiatives related to diversity, inclusion, and women’s health. Building patient trust in data management and usage is a key challenge for the industry. The industry is struggling with public engagement, but emerging technologies can help break down barriers and improve outreach efforts. ALL COVERAGE Drug Development SCOPE Summit 2025 Key Takeaways: A Look Inside, Outside and Beyond the Cybersecurity Wall Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night. February 13, 2025 · 1 min read · Lori Ellis Drug Development Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity. February 17, 2025 · 1 min read · Lori Ellis Drug Development Site Survival: Why Clinical Research Sites Need a Lifeline Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials. February 19, 2025 · 1 min read · Lori Ellis Drug Development Diversity at the Forefront: Life Sciences Industry Champions Inclusive Representation The industry remains unwavering in the commitment to increased clinical trial accessibility and representation. February 25, 2025 · 1 min read · Lori Ellis Drug Development Beyond Dr. Google: The Roles of Industry and AI in Fighting Misinformation and Fueling Patient Empowerment As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount. February 27, 2025 · 1 min read · Lori Ellis Drug Development Building Patient Trust Amid an Environment of Distrust While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare. February 28, 2025 · 1 min read · Lori Ellis Drug Development The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty In the current legal and political landscape, it is all about survival for DEI initiatives. March 3, 2025 · 1 min read Drug Development Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025. March 5, 2025 · 1 min read · Lori Ellis

In the current legal and political landscape, it is all about survival for DEI initiatives. Chris Hart , partner at Foley Hoag joins Lori Ellis, head of insights at BioSpace to discuss the impact of state actions on patient data. Hart highlights the chilling effect of states suing doctors from other states, potentially reducing telemedicine appointments. He notes that shield laws in states like New York and Massachusetts protect patient data, but hostile states may challenge this. Hart also addresses the risk to patient trust in states without shield laws and the broader implications for diversity, equity, and inclusion (DEI) initiatives. He warns that DEI programs are under threat, with significant changes in the legal and political landscape potentially jeopardizing these efforts. Key Takeaways The Dobbs decision has created a chilling effect on telemedicine appointments and doctors’ willingness to provide services across state lines, due to the risk of civil or criminal litigation. Patient data protection is uncertain, especially in states without strong shield laws. There are concerns about hostile state governments attempting to obtain sensitive patient data through legal processes. The political and legal environment has made reproductive healthcare and diversity, equity, and inclusion (DEI) data particularly vulnerable, even though HIPAA and privacy laws still apply. Organizations are rethinking their DEI initiatives to reduce legal risk, but the survival of these programs is uncertain under the current administration’s scrutiny. ALL COVERAGE Drug Development SCOPE Summit 2025 Key Takeaways: A Look Inside, Outside and Beyond the Cybersecurity Wall Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night. February 13, 2025 · 1 min read · Lori Ellis Drug Development Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity. February 17, 2025 · 1 min read · Lori Ellis Drug Development Site Survival: Why Clinical Research Sites Need a Lifeline Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials. February 19, 2025 · 1 min read · Lori Ellis Drug Development Diversity at the Forefront: Life Sciences Industry Champions Inclusive Representation The industry remains unwavering in the commitment to increased clinical trial accessibility and representation. February 25, 2025 · 1 min read · Lori Ellis Drug Development Beyond Dr. Google: The Roles of Industry and AI in Fighting Misinformation and Fueling Patient Empowerment As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount. February 27, 2025 · 1 min read · Lori Ellis Drug Development Building Patient Trust Amid an Environment of Distrust While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare. February 28, 2025 · 1 min read · Lori Ellis Drug Development The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty In the current legal and political landscape, it is all about survival for DEI initiatives. March 3, 2025 · 1 min read Drug Development Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025. March 5, 2025 · 1 min read · Lori Ellis

While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare. During the conversation, Sam Srivastava, CEO at WCG Clinical emphasizes the importance of earning patient trust through community engagement and storytelling, beyond just data. He highlights the need for the life sciences industry to expand outreach beyond specialists to include primary care, academic centers, and advocacy groups. He concludes that expertise and personalized outreach are crucial for both patients and sites to navigate clinical trials effectively. Key Takeaways The life sciences industry needs to engage with patients’ stories, connected communities, and trusted health advisors. Engaging with healthcare professionals (HCPs) should involve a wider net, including specialists, academic medical centers, research sites, communities, and advocacy groups. Engagement needs to go beyond traditional methods like lunch and learns. Effective engagement with the general public requires not just data platforms, but also personalized outreach and follow-up from trusted advisors to help demystify clinical trials and empower individuals to make informed decisions. ALL COVERAGE Drug Development SCOPE Summit 2025 Key Takeaways: A Look Inside, Outside and Beyond the Cybersecurity Wall Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night. February 13, 2025 · 1 min read · Lori Ellis Drug Development Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity. February 17, 2025 · 1 min read · Lori Ellis Drug Development Site Survival: Why Clinical Research Sites Need a Lifeline Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials. February 19, 2025 · 1 min read · Lori Ellis Drug Development Diversity at the Forefront: Life Sciences Industry Champions Inclusive Representation The industry remains unwavering in the commitment to increased clinical trial accessibility and representation. February 25, 2025 · 1 min read · Lori Ellis Drug Development Beyond Dr. Google: The Roles of Industry and AI in Fighting Misinformation and Fueling Patient Empowerment As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount. February 27, 2025 · 1 min read · Lori Ellis Drug Development Building Patient Trust Amid an Environment of Distrust While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare. February 28, 2025 · 1 min read · Lori Ellis Drug Development The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty In the current legal and political landscape, it is all about survival for DEI initiatives. March 3, 2025 · 1 min read Drug Development Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025. March 5, 2025 · 1 min read · Lori Ellis